REGENXBIO Announces RGX-314 Data Presentations at American Society of Retina Specialists Annual Meeting
10/01/2021 - 07:05 AM
ROCKVILLE, Md. , Oct. 1, 2021 /PRNewswire/ --
Data for Cohort 1 with three months of follow-up from the RGX-314 Phase II trial for the treatment of diabetic retinopathy (ALTITUDE® ) to be presented REGENXBIO Inc. (Nasdaq: RGNX) today announced that data from the RGX-314 clinical trials will be presented in three oral presentations at the American Society of Retina Specialists Annual Meeting taking place in San Antonio , TX, from October 8 to 12, 2021 . The presentations will include interim results at three months of follow-up for patients in Cohort 1 (dose level: 2.5x1011 genome copies per eye (GC/eye)) of the Phase II ALTITUDE® trial in patients with diabetic retinopathy (DR). This trial is designed to evaluate the in-office, suprachoroidal delivery of RGX-314.
The American Society of Retina Specialists Annual Meeting presentations include:
Title: Suprachoroidal Delivery of RGX-314 for Diabetic Retinopathy Without CI-DME: Early Results From the Phase II ALTITUDE StudyPresenter: Dennis Marcus, M.D., F.A.S.R.S., Southeast Retina CenterSession Title: Diabetic Retinopathy 2 SymposiumDate/Time: Saturday, October 9, 2021, from 11:31 to 11:35 a.m. CT Type: Oral presentation
Title: Subretinal Delivery of RGX-314 for Neovascular AMD: End of Study Phase I/IIa Results (Encore Presentation)Presenter: Lejla Vajzovic, M.D., F.A.S.R.S., Surgical & Medical Retina Specialist & Director of Duke Eye Center Continuing Medical EducationSession Title: Wet AMD 1 SymposiumDate/Time: Monday, October 11, 2021, from 8:38 to 8:44 a.m. CT Type: Oral presentation
Title: Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study (Encore Presentation)Presenter: Mark Barakat, M.D., F.A.S.R.S., Director of Research, Retinal Consultants of Arizona ; Clinical Assistant Professor, University of Arizona College of Medicine, Phoenix Session Title: Wet AMD 1 SymposiumDate/Time: Monday, October 11, 2021, from 8:44 to 8:50 a.m. CT Type: Oral presentation
About RGX-314
RGX-314 is being investigated as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal conditions. RGX-314 consists of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF). RGX-314 is believed to inhibit the VEGF pathway by which new, leaky blood vessels grow and contribute to the accumulation of fluid in the retina.
REGENXBIO is advancing research in two separate routes of administration of RGX-314 to the eye, through a standardized subretinal delivery procedure as well as delivery to the suprachoroidal space. REGENXBIO has licensed certain exclusive rights to the SCS Microinjector® from Clearside Biomedical, Inc. to deliver gene therapy treatments to the suprachoroidal space of the eye.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
SCS Microinjector® is a trademark of Clearside Biomedical, Inc. All other trademarks referenced herein are registered trademarks of REGENXBIO.
Contacts:
Tricia Truehart Investor Relations and Corporate Communications 347-926-7709ttruehart@regenxbio.com
Investors:Brendan Burns , 212-600-1902brendan@argotpartners.com
Media:David Rosen , 212-600-1902david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-rgx-314-data-presentations-at-american-society-of-retina-specialists-annual-meeting-301389567.html
SOURCE REGENXBIO Inc.
RGNX Rankings
#4288 Ranked by Stock Gains
RGNX Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Rockville
About RGNX
regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.